Table 2.
Published clinical trials of targeted therapy in TETs.
| First Author, Year (Study Name) | Phase | TCs (n) | TMs (n) | Experimental Drug | mPFS | ORR, % | DCR, % | G3-G4 AEs n (%) |
|---|---|---|---|---|---|---|---|---|
| NCT02220855 | II | 0 | 14 | buparlisib | 11.1 months | 7.1% | 50% | 7 (50%) |
| Rajan A et al. 2014 (NCT00965250) | II | 12 | 37 | cixutumumab | 9.9 for TMs and 1.7 for TCs | 14% for TMs and 0% for TCs | 89% for TMs and 42% for TCs | 29 (59.2%) |
| Palmieri G et al. 2002 | II | 6 | 10 | octreotide and prednisone | 14 months | 37% | 75% | 0 (0%) |
| Loehrer PJ Sr et al. 2004 (NCT00003283) | II | 6 | 32 | octreotide ± prednisone | 8.8 months for TMs and 4.5 months for TCs | 37.5% for TMS and 0% for TCs | 67.1% | 8 (21.5% G4-5) |
| Kirzinger L et al. 2016 (NCT00332969) | II | 2 | 15 | octreotide LAR and prednisone | N/A | 100% for TMs 0% for TCs | N/A | 3 (17.6%) |
| Gubens MA et al. 2015 (NCT00718809) | II | 9 | 12 | saracatinib | 5.7 months for TMs and 3.6 months for TCs | 0% | 42,9% | 3 (14.3%) |
| Giaccone G et al. 2009 | II | 5 | 2 | imatinib | 2 months | 0% | 100% for TMs and 0% for TCs | 2 (28.6%) |
| Palmieri G et al. 2012 | II | 3 | 12 | imatinib | 3 months | 0% | 8.3% for TMs and 0% for TCs | 0 (0%) |
| Thomas A et al. 2015 (NCT01621568) | II | 24 | 16 | sunitinib | 7.2 months for TCs and 8.5 months for TMs | 26% for TCs and 6% for TMs | 91% for TCs and 81% for TMs | 28 (70%) |
| Bedano PM et al. 2008 (NCT00369889) | II | 7 | 11 | erlotinib and bevacizumab | N/A | 0% | 60% | N/A |
| Sato J et al. 2020 (REMORA trial) | II | 42 | 0 | lenvatinib | 9.3 months | 38% | 95% | 8 (19%) |
| Giaccone G et al. 2011 (NCT00589290) | II | 16 | 25 | belinostat | 5.8 months | 8% for TMs and 0% for TCs | 25% | 6 (14.6%) |
| Thomas A et al. 2014 (NCT01100944) | I/II | 14 | 12 | belinostat and chemotherapy | not reached for TMs and 7.2 months for TCs | 64% for TMs and 21% for TCs | 100% for TMs and 93% for TCs | 20 (76.9%) |
| Besse B et al. 2018 (NCT01011439) | II | 52 | 20 | milciclib | 6.8 months | 3.7% | 75.9% | 22 (30.6%) |
| Besse B et al. 2018 (NCT01301391) | II | 13 | 17 | milciclib | 9.8 months | 4.2% | 83.3% | 14 (46.7%) |
| Abdul Razak AR et al. 2016 (NCT01607905) | I | 0 | 4 | selinexor | N/A | 25% | 100% | N/A |
Abbreviations: TCs, thymic carcinomas; TMs, thymomas; mPFS, median progression free survival; ORR, overall response rate; DCR, disease control rate; AEs, adverse events; N/A, data not available. Note: data presented as No (%).